NEW YORK, NY, and PASADENA, CA, November 9, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in cash

NEW YORK , NY,  November 08, 2022  -  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, October 18, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, October 17, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business

NEW YORK, NY, October 12, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team . Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer.

NEW YORK, NY, October 12, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an

NEW YORK, NY, September 6, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 17th Annual BioPharma Conference on Thursday, September 8 at 11:20 a.m.

NEW YORK, NY,  August 04, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, July 15, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the close of business

NEW YORK, NY, July 14, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.